Abstract: A method of treating a surface of a substrate using modified urushiol derived from Toxicodendron vernicifluum is provided. More particularly, the reactivity of a hydroxyl group of urushiol extracted from fresh Toxicodendron vernicifluum is removed before the lacquer is used as a UV coating agent for a substrate such as a steel sheet. Therefore, the substrate may have high antibacterial activity, and excellent appearance and functionalities such as far-infrared radiation, blocking of electromagnetic waves, enhanced corrosion resistance, high crosslinking speed when a low content of a photoinitiator is used, excellent surface gloss and high scratch resistance.

Abstract: The instant invention relates to a solid product comprising a liquid biologically active agent which is intimately associated to a stabilizing agent; particularly a solid product that can be reconstituted to a clear, stable, stabilized nanodispersion or loaded micelles comprising a polymer as a stabilizing agent and a liquid, preferably water immiscible, biologically active agent. The instant invention is further directed toward a process for the production of the above solid product; particularly to micelles or nanodispersions produced by hydration of a cake or powder of the solid product, produced via an effective treatment of a stabilized solution comprising for example a polymer as a stabilizing agent, such as an amphiphilic block copolymer or a small molecular weight surfactant, loaded with a liquid biologically active agent, such as propofol, an optional additive, and a suitable solvent.

Abstract: The present invention relates to a pharmaceutical excipient comprising a mixture of sugar alcohol and chitin and/or chitin derivatives, a method for its preparation and use thereof.

Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.

Abstract: Compounds of formula (I) wherein X is H or F and pharmaceutically acceptable salts thereof are useful as anesthetics.

Abstract: Methods for treating ocular and periocular disorders by administration to a human patient of a therapeutically effective amount of a compound that modulates muscle action.

Abstract: Rapid opioid detoxification procedures are provided which include sedating a patient with an anesthetic agent having a short full recovery period. The patient is administered an opioid antagonist while sedated and can be revived to an ambulatory condition within eight hours of initiating therapy. The described methods for detoxification also include administering a diarrhea suppressant, such as octreotide acetate, to limit this unfortunate side effect of the detoxification.

Abstract: Delivery compositions and substrates for imparting a volatile active agent to a surface are disclosed herein. To achieve the delivery of the volatile component, a delivery composition of a carbohydrate matrix and a volatile component is incorporated into the carbohydrate matrix to stabilize the volatile for extended periods of time. The delivery composition further comprises a self-generating expelling agent to expel the volatile component onto the contaminated surface or skin upon addition of a triggering agent.

Abstract: The present invention is directed to a topical pharmaceutical composition which comprises a compound of formula (I), such as hydroxytyrosol, or a pharmaceutically acceptable salt, solvate, prodrug or isomer thereof, and a pharmaceutically acceptable carrier wherein R1, R2 and R3 take different values, and the use of said composition as 10 medicament in the prevention of sexually transmitted diseases (STDs), such as HIV-infection.

Abstract: Provided herein is a stable pharmaceutical product comprising a dry powder inhalation device, and a pharmaceutical composition that comprises R,R-Formoterol L-tartrate salt, in particular crystalline R,R-formoterol L-tartrate; and ciclesonide.

Abstract: Transdermal therapeutic systems that contain 4-n-butylresorcinol as an active ingredient.

Abstract: The present invention relates to a method for preparing an oral lyophilizate composition comprising: a) forming a liquid phase by using at least one homogenising agent having tensioactive properties, said liquid phase comprising at least an active pharmaceutical ingredient, a filler and/or a binding agent and a solvent, b) lyophilizing said liquid phase to form the oral lyophilizate composition.

Abstract: Methods of treating stuttering include treating people with gamma-aminobutyric acid (GABA) receptor modulators, including cyclopyrrolones. A second active agent may be used with GABA receptor modulators. Active enantiomers, active metabolites, and pharmaceutically acceptable salts of gamma-aminobutyric acid receptor modulators, including cyclopyrrolones, are acceptable components of the compositions. The cyclopyrrolone class of modulators includes pagoclone, suriclone, zopiclone, 2-(7-chloro-2-naphthyridin-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindolin-1-one, 2-(7-chloro-2-naphthyridin-1,8-yl)isoindolin-1-yl-4-acetamidobutyrate, and 2-(7-chloro-1,8-naphthyridin-2yl)-3-(5-methyl-5-hydroxy-2-oxohexyl)-1-isoindolinone.

Abstract: The invention provides novel pharmaceutical compositions comprising the active ingredient propofol. Preferably, propofol is dissolved in at least one semifluorinated alkane. The compositions, which are preferably liquid or gel-like, may optionally comprise further excipients. They may be used as fill material in capsules, as buccal or nasal sprays, or as aerosols for pulmonary administration. They are particularly useful for the transmucosal administration of propofol.

Abstract: This invention pertains to a method of modifying biocides obtained from biological sources, namely polyphenols. The modified biocide may have protective groups to reduce or prevent the oxidation of these phenols. The protective groups may also control the rate of hydrolyzation with regards to biocide efficacy. This invention also includes a method wherein the modified biocide may be incorporated and stabilized into a substrate like plastic.

Abstract: Hydrogel particles include: (A) a water-insoluble complex containing catechins; (B) a compound which forms chelate together with divalent or trivalent metal ions; (C) a divalent or trivalent metal salt; (D) a gel-forming agent; and (E) water.

Abstract: Solids, including fibers can be easily removed from olive juice by mixing the olive juice with a water-miscible solvent to form two phases and separating the phases. Preferably the solvent is ethanol.

Abstract: A formulation to reduce the numbers of bacteria, particularly Gram positive bacteria, in a space such as a waste disposal bin, via the vapor phase, and active over a long period, typically several weeks. The product comprises one or more essential oils or essential oil components plus a mixture of volatile and non-volatile solvents, on a carrier such as a non-woven, sintered plastic or cardboard.

Abstract: A dental curable composition comprises (A) a polymerizable monomer and (B) an organic amine-based polymerization initiator, wherein (A?) a long-chain polymerizable monomer having a chain length of 17 or more atoms is contained in the component (A) and/or (C) a soft resin material are/is contained in the composition, and when the amount (parts by weight) based on 100 parts by weight of the component (A) of the component (A?) is represented by [a?] and the amounts (parts by weight) based on 100 parts by weight of the total of the components (A) and (B) of the components (A), (B) and (C) are represented by (a), (b) and (c), respectively, 70?(a)?99.99, 0.01?(b)?5 30, 1?[a?]/5+(c)/1, 0?[a?]?95, and 0?(c)?250.

Abstract: A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.

Abstract: A method of treating a patient infected with a lipid encapsulated virus by administering to the patient about 1000 mg to about 5000 mg per day of a nutritional supplement having from about 40 to about 80 wt. % L-lysine, from about 20 to about 50 wt. % butylated hydroxytoluene and from about 1 to about 10 wt. % Echinacea. Administration of the nutritional supplement inhibits ulcer formation resulting from lipid encapsulated virus infections such as herpes simplex I and II infections.

Abstract: The invention relates to synergistic mixtures of o-phenylphenol with other microbicidally active compounds, such as bronopol (2-bromo-2-nitro-1,3-propanedial), 2-methyl-2H-isothiazol-3-one, 1,2-dibromo-2,4-dicyanobutane.

Abstract: Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are compositions for lightening or darkening the pigmented tissues or treating a pigmented tissue disease.

Abstract: A method includes obtaining a biological sample from a subject that does not display a symptom of Painful Bladder Syndrome (PBS). The method also includes analyzing the biological sample for a mutated form of NAD(P)H dehydrogenase [quinone], also known as Quinone Oxidoreductase 1, abbreviated NQO1, or a mutation of a NQO1 gene. The method also includes determining a risk of PBS for the subject based on analyzing the biological sample. In some methods, the mutation determined to present an increased risk is a cytosine to thymine nucleotide substitution at a position that leads to a proline to serine amino acid substitution at amino acid position 187 to produce a protein NQO1P187S. Another method includes selecting a subject that has above normal risk of Painful Bladder Syndrome (PBS) or is expressing a symptom of PBS, and treating the subject with a therapeutically effective amount of an antioxidant.

Abstract: The invention comprises compounds, methods of making, and methods of using. The compounds may have a backbone and three appended functional groups: one lipid, one hydrophilic polymer, and one carbohydrate. Specific functional groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutriceuticals, and the like. A variety of linkers between the backbone and functional groups may also be selected to optimize performance.

Abstract: A (?)-stereoisomer of formula (I): (formula I), wherein X is H or F; or a pharmaceutically acceptable salt or pro drug thereof, is useful as an anesthetic.

Abstract: A composition including a strawberry-derived polyphenol highly effective for oral administration or external use. A composition for oral administration or external use is obtained by subjecting a hot water extract of strawberry to adsorption chromatography using an aromatic synthetic absorbent, removing the fractions passing through the column and fractions eluted with water, and then eluting with a 5 to 60% aqueous ethanol solution.

Abstract: The present invention provides an HDL comprising an agent selected from the group consisting of antiproteases, antixoxidants, antimitotics, anti-apoptotic agents and agents involved in the iron metabolism for use as a medicament.

Abstract: Methods for regulating the formation of a sulfilimine crosslink in a subject by administering a sulfilimine crosslink modulator are disclosed The sulfilimine modulator may inhibit or create a sulfilimine crosslink and maybe useful for treating a disease, such as cancer The sulfilimine crosslink may be between two or more peptides

Abstract: A preparation method of drug loaded emulsion is disclosed. The method comprises the steps of: preparing a non-self emulsifying O/W blank emulsion having no active ingredients; then, adding therapeutically effective amount of active ingredients to the 0/W blank emulsion, adjusting pH to distribute the active ingredients through the membrane to obtain the desired emulsion.

Abstract: The present invention relates to liposomal pharmaceutical preparations which include active agents such as antiseptic agents, wound-healing agents, or combinations thereof, useful in the treatment of external wounds. The active agents are encapsulated in liposomes, and the liposomes are incorporated in pharmaceutical preparations such as liquids, ointments, gels, lotions, or creams capable of delivering the active agents to external wound sites. The invention further relates to methods of preparation of the liposomes and the pharmaceutical preparations, and to methods of treatment of external wounds and ophthalmic infections.

Abstract: An alkylated hydroxyaromatic compound prepared by reacting at least one hydroxyaromatic compound with a branched olefinic oligomer having from about 20 to about 80 carbon atoms in the presence of a acid catalyst. The alkylated hydroxyaromatic compound has been determined to be substantially free of endocrine disruptive chemicals when the effects were quantified on pubertal development and thyroid function in the intact juvenile female rat.

Abstract: A method of improving the appearance of facial texture may comprise the step of applying a composition comprising an effective amount of a material that regulates hyaluronic acid synthesis to an area of textured facial skin, wherein the composition is applied for a period of time sufficient for the material to improve the appearance of the facial texture. In some embodiments, the material that regulates hyaluronic acid synthesis is hexyldecanol. The method may also include the step of identifying facial texture on a facial skin surface. In particular embodiments, the facial skin texture is selected from the group consisting of macro-texture, micro-texture, and combinations thereof.

Abstract: The invention provides intravenous formulations of propofol in an oil-in-water emulsion, having a combination of preservatives.

Abstract: Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including an antiseptic such as halogenated phenols, bisphenols, diphenyl ethers, anilides and derivatives thereof, and combinations thereof. The compositions can also include an enhancer component, a surfactant, a hydrophobic component, and/or a hydrophilic component. Such compositions provide effective topical antimicrobial activity and are accordingly useful in the treatment and/or prevention of conditions that are caused, or aggravated by, microorganisms (including viruses).

Abstract: A wipe that contains a fibrous web on which is coated an antimicrobial composition is provided. The composition includes a botanical oil derived from a plant (e.g., thymol, carvacrol, etc.). Because the botanical oil is volatile and tends to evaporate and lose efficacy during storage and prior to use, a protein is also employed in the composition to enhance long term stability of the oil and, in turn, its antimicrobial efficacy. The protein is “film-forming” in the sense that it tends to form a substantially continuous film when coated onto a surface of the fibrous web. Because such proteins are typically stiff and brittle in nature, a continuous film would restrict the ability of the fibers to move and bend, thereby reducing web flexibility and drape. Thus, it is typically desired that the antimicrobial composition form a discontinuous coating on the fibrous web.

Abstract: A method for forming an antimicrobial composition that includes mixing an antimicrobially active botanical oil (e.g., thymol, carvacrol, etc.) and protein within a melt blending device (e.g., extruder) is provided. Despite the problems normally associated with melt processing proteins, the present inventors have discovered that the processing conditions and components may be selectively controlled to allow for the formation of a stable, melt-processed composition that is able to exhibit good mechanical properties. For example, the extrusion temperature(s) and shear rate employed during melt blending are relatively low to help limit polypeptide dissociation, thereby minimizing the impact of aggregation and embrittlement.

Abstract: A method for forming a composition that includes mixing an antimicrobially active botanical oil (e.g., thymol, carvacrol, etc.) and a modified starch polymer within a melt blending device (e.g., extruder) is provided. Unlike the problems associated with proteins, the use of starch polymers allows for a greater degree of flexibility in the processing conditions and is still able to achieve good properties in the resulting composition. The present inventors have also discovered that a plasticizer may be employed to facilitate melt processing of the starch, as well as to enhance the ability of the botanical oil to flow into the internal structure of the starch where it can be retained in a stable manner. The composition is also typically generally free of solvents. In this manner, the starch will not generally disperse before use and prematurely release the botanical oil.

Abstract: Oregano extract can act as a stimulant, yet it does not interfere with sleep patterns or induce nervousness the way many stimulants such as caffeine can. It also has the benefits of promoting improved vigilance, improving attention and ability to focus on a task, and improving general alertness.

Abstract: An oil-in-water emulsion that is environmentally friendly and also exhibits antimicrobial activity is provided. More specifically, the oil phase of the emulsion includes a botanical oil derived from a plant (e.g., thymol, carvacrol, etc.). Because the botanical oil tends to leach out of the emulsion during storage and before it is used in the desired application, a water-dispersible polymer is also employed in the aqueous phase of the emulsion to enhance long term stability of the oil and, in turn, antimicrobial efficacy. Without intending to be limited by theory, it is believed that the water-dispersible polymer can effectively encapsulate the botanical oil within the emulsion and inhibit its premature release. Once the emulsion is formed, water can then be removed so that it becomes a substantially anhydrous concentrate. In this manner, the water-dispersible polymer will not generally disperse before use and prematurely release the botanical oil.

Abstract: Olive juice is de-bittered by raising the pH to about 9 while increasing the temperature. Under these conditions, bitter tasting compounds are hydrolyzed, and the resulting juice has both an increased hydroxytyrosol content, and is non-bitter. This extract can be further processed, or used as a component of a nutritional composition or nutritional supplement.

Abstract: Several terpene glycosides (e.g., mogroside V, paenoiflorin, geniposide, rubusoside, rebaudioside A, steviol mono-side and stevioside) were discovered to enhance the solubility of a number of pharmaceutically and medicinally important compounds, including but not limited to, paclitaxel, camptothecin, curcumin, tanshinone HA, capsaicin, cyclosporine, erythromycin, nystatin, itraconazole, celecoxib, clofazimine, digoxin, oleandrin, nifedipine, and amiodarone. The use of the diterpene glycoside rubusoside and monoterpene glycoside paenoiflorin increased solubility in all tested compounds. The terpene glycosides are a naturally occurring class of water solubility-enhancing compounds that are non-toxic and that will be useful as new complexing agents or excipients in the pharmaceutical, agricultural (e.g., solubilizing pesticides), cosmetic and food industries.

Abstract: The present invention relates to a formulation comprising (a) at least one pesticide; and (b) at least one non-ionic surfactant of formula (I): R1—O-(AO)x—(H); wherein R1 represents straight-chain or branched alkyl having 4 to 20 carbon atoms; AO is ethyleneoxy, propyleneoxy or a mixture of ethyleneoxy and propyleneoxy; and x correspond to values from 2 to 30; and (c) at least one ionic tristyrylphenyl alkoylate; and (d) at least one oil; and (e) water, wherein the pesticide is present in the aqueous phase in form of a suspension and the oil is essentially free of pesticide.

Abstract: A (?)-stereoisomer of formula (I): (formula I), wherein X is H or F; or a pharmaceutically acceptable salt or prodrug thereof, is useful as an anesthetic.

Abstract: The invention relates to a novel combined disinfection and decontamination agent comprising at least one vitamin, at least one metal ion, at least one active-surface compound, and at least one further antimicrobial active substance. The agent according to the invention surprisingly shows nearly complete nucleic acid disintegration in addition to an improved disinfectant effect. The agent can be successfully used as a combined decontamination and disinfection agent for skin, mucous membranes, hands, wounds, and/or hair, and instruments and surfaces of all kinds.

Abstract: The present invention relates to the use of essential oil compounds as histomonastats. An example of a essential oil compound of the invention is cinnamaldehyde.

Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.

Abstract: Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are nanoparticle compositions for lightening the pigmented tissues or treating a pigmented tissue related disease.

Abstract: The present invention relates to methods for modulating the inflammatory response of respiratory tract cells using an agent that increases ceramide levels in the cells of the respiratory tract.

Abstract: Provided herein are compositions and methods for the treatment of soft tissue injury, sports-related injury, physical overuse of muscles, ligaments or joints, and trauma, traumatic stress or sudden jolts on bones and tissues in an individual. Described herein are pharmaceutical compositions comprising a vasoconstrictor and, optionally, a topical analgesic and methods of using said compositions for the treatment of a variety of soft tissue injuries.